Skip to main content

Table 1 Study characteristics

From: Interventions to decrease the risk of adverse cardiac events for patients receiving chemotherapy and serotonin (5-HT3) receptor antagonists: a systematic review

Reference Study period, country Study design, # of patients 5-HT3 dose/day Intervention, examination timing Outcomes examined
Hesketh [18] NR, USA Non-RCT, 44 IV dolasetron 1.2 mg/kg, 1.8 mg/kg, 2.4 mg/kg 30 mins before chemotherapy ECG, 1–2 hrs and 24–48 hrs PR, QT
Gralla [19] August 2000 to October 2001, Germany, Italy, UK, Netherlands, Russia RCT, 98 IV palonosetron 0.25 mg, IV palonosetron 0.75 mg, IV ondansetron 32 mg 30 mins before chemotherapy ECG, 15 mins, 24 hrs, 1 wk Mortality, QT
Kim [20] April 2002 to October 2002, South Korea RCT, 114 IV dolasetron 100 mg 30 mins before and 200 mg p.o. 2-5 days after chemotherapy, IV ondansetron 8 mg 30 mins before and IV ondansetron 16 mg 2–4 hrs plus an additional 16 mg/day p.o. 2-5 days after chemotherapy ECG, 15 mins, 24 hrs, 1 wk ECG findings unspecified
  1. ECG: electrocardiogram; IV: intravenous; NR: not reported; Non-RCT: non-randomized clinical trial; p.o.: administered orally; RCT: randomized controlled trial.